Senior Correspondent, London
Ben's Feed
Apr 16, 2014
Apr 15, 2014
Apr 14, 2014

GSK faces criminal bribery investigation in Poland

LONDON/WARSAW (Reuters) – GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

Poland’s Central Anti-Corruption Bureau, or CBA, said on Monday that 13 people had been charged in connection with the investigation launched by Polish prosecutors.

Apr 14, 2014
Apr 13, 2014
Apr 13, 2014
Apr 13, 2014
Apr 11, 2014
Apr 11, 2014

Doctors welcome hepatitis C drug rivals, Gilead still leads

LOS ANGELES/LONDON (Reuters) – Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

Gilead, under fire from insurers and legislators for the $1,000-a-pill price of its Sovaldi drug, presented pivotal data on Friday at the European Association for the Study of the Liver conference in London, showing a cure rate of 94 percent after eight weeks of treatment with its experimental two-drug pill.

Apr 10, 2014

Hospira wins UK case to overturn patents on Roche drug Herceptin

LONDON (Reuters) – Hospira has successfully overturned two patents on Roche’s blockbuster breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country.

A ruling handed down by the High Court in London on Thursday determined that both the 115 and 455 patents on the drug, which relate to the drug’s dosage and its composition, were invalid.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben